GlassScriptPhysician profile
James G Day
NPI 1841218948
$1,482.50
in general payments reported to CMS, 2019-2025
23 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $38.67 · 2021: $163 · 2023: $201 · 2024: $329 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.69 | 2023-2025 | Qulipta, Linzess, Viberzi |
| Pfizer INC. | $245.39 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $197.66 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $137.62 | 2021 | |
| Novo Nordisk INC | $132.17 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $46.84 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $45.55 | 2023-2024 | Mounjaro |
| Daiichi Sankyo INC. | $45.20 | 2024-2025 | Injectafer |
| Dexcom, INC. | $42.17 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $37.81 | 2019-2025 | Rexulti |
| Amgen INC. | $34.33 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $34.02 | 2023-2024 | Arexvy, Shingrix |
| Cequr Corporation | $31.20 | 2023 | Cequr Simplicity |
| Tris Pharma INC | $28.84 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $22.84 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $20.90 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $17.53 | 2025 | Nexletol |
| Vertex Pharmaceuticals Incorporated | $14.33 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.73 | 2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.65 | 2019 | |
| Amarin Pharma, INC. | $12.39 | 2020 | |
| Mylan Specialty L.P. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.